The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Official Title: Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Study ID: NCT02291913
Brief Summary: Many patients with ER-positive or PR-positive breast cancer are treated with endocrine therapy. Although most ER/PR-positive tumors initially respond to hormonal therapy, patients often experience disease progression. Everolimus, in combination with exemestane, has shown activity in endocrine-resistant disease. This study will evaluate the efficacy of Everolimus+ anti-estrogen therapy in patients with ER-positive metastatic breast cancer who have progressed after receiving anti-estrogen therapy.
Detailed Description: This is a multi-centered, open-labeled, Phase II study on metastastic breast cancer (MBC). The patient population includes locally recurrent or MBC patients with cytologically or histologically confirmed hormone receptor-positive breast cancer who have demonstrated disease progression on prior anti-estrogen therapy or therapies. Investigators propose to evaluate the efficacy of Everolimus in patients with ER-positive (estrogen receptor-positive) metastatic breast cancer who have progressed on anti-estrogen therapy. Forty-six (46) patients are planned for enrollment in the trial.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Florida Cancer Specialists-South, Fort Myers, Florida, United States
Memorial Cancer Center, Hollywood, Florida, United States
Woodlands Medical Specialists, Pensacola, Florida, United States
Florida Cancer Specialists-East, West Palm Beach, Florida, United States
Hope Cancer Center, Terre Haute, Indiana, United States
Tennessee Oncology, Chattanooga, Tennessee, United States
Tennessee Oncology PLLC, Nashville, Tennessee, United States
Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
Name: Denise A. Yardley, MD
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR